img

Global Pandemic Influenza Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pandemic Influenza Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Influenza vaccines treat influenza by developing antibodies in the body within two weeks after vaccination. These antibodies protect against infections with the help of the attenuated viruses in the vaccine. These vaccines contain killed or inactivated strains of the influenza virus.
The global Pandemic Influenza Vaccine market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Pandemic Influenza Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Pandemic Influenza Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Pandemic Influenza Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Pandemic Influenza Vaccine include CSL, GSK, Sanofi Pasteur, Mylan, AstraZeneca, Pfizer and Johnson & Johnson, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Pandemic Influenza Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Pandemic Influenza Vaccine by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Pandemic Influenza Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Pandemic Influenza Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


CSL
GSK
Sanofi Pasteur
Mylan
AstraZeneca
Pfizer
Johnson & Johnson
By Type
Whole Virus Vaccines
Split Virus Vaccines
Subunit Vaccines
By Application
For Children (6 months to 3 years)
For Adults and Children over 3 years
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Pandemic Influenza Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Pandemic Influenza Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pandemic Influenza Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Pandemic Influenza Vaccine Definition
1.2 Market by Type
1.2.1 Global Pandemic Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Whole Virus Vaccines
1.2.3 Split Virus Vaccines
1.2.4 Subunit Vaccines
1.3 Market Segment by Application
1.3.1 Global Pandemic Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 For Children (6 months to 3 years)
1.3.3 For Adults and Children over 3 years
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pandemic Influenza Vaccine Sales
2.1 Global Pandemic Influenza Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Pandemic Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Pandemic Influenza Vaccine Revenue by Region
2.3.1 Global Pandemic Influenza Vaccine Revenue by Region (2018-2024)
2.3.2 Global Pandemic Influenza Vaccine Revenue by Region (2024-2034)
2.4 Global Pandemic Influenza Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pandemic Influenza Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Pandemic Influenza Vaccine Sales Quantity by Region
2.6.1 Global Pandemic Influenza Vaccine Sales Quantity by Region (2018-2024)
2.6.2 Global Pandemic Influenza Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pandemic Influenza Vaccine Sales Quantity by Manufacturers
3.1.1 Global Pandemic Influenza Vaccine Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Pandemic Influenza Vaccine Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Pandemic Influenza Vaccine Sales in 2022
3.2 Global Pandemic Influenza Vaccine Revenue by Manufacturers
3.2.1 Global Pandemic Influenza Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Pandemic Influenza Vaccine Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pandemic Influenza Vaccine Revenue in 2022
3.3 Global Pandemic Influenza Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Pandemic Influenza Vaccine, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pandemic Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pandemic Influenza Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pandemic Influenza Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Pandemic Influenza Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pandemic Influenza Vaccine Sales Quantity by Type
4.1.1 Global Pandemic Influenza Vaccine Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Pandemic Influenza Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pandemic Influenza Vaccine Revenue by Type
4.2.1 Global Pandemic Influenza Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Pandemic Influenza Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pandemic Influenza Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Pandemic Influenza Vaccine Price by Type
4.3.1 Global Pandemic Influenza Vaccine Price by Type (2018-2024)
4.3.2 Global Pandemic Influenza Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pandemic Influenza Vaccine Sales Quantity by Application
5.1.1 Global Pandemic Influenza Vaccine Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Pandemic Influenza Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pandemic Influenza Vaccine Revenue by Application
5.2.1 Global Pandemic Influenza Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Pandemic Influenza Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pandemic Influenza Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Pandemic Influenza Vaccine Price by Application
5.3.1 Global Pandemic Influenza Vaccine Price by Application (2018-2024)
5.3.2 Global Pandemic Influenza Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pandemic Influenza Vaccine Sales by Company
6.1.1 North America Pandemic Influenza Vaccine Revenue by Company (2018-2024)
6.1.2 North America Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024)
6.2 North America Pandemic Influenza Vaccine Market Size by Type
6.2.1 North America Pandemic Influenza Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Pandemic Influenza Vaccine Revenue by Type (2018-2034)
6.3 North America Pandemic Influenza Vaccine Market Size by Application
6.3.1 North America Pandemic Influenza Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Pandemic Influenza Vaccine Revenue by Application (2018-2034)
6.4 North America Pandemic Influenza Vaccine Market Size by Country
6.4.1 North America Pandemic Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Pandemic Influenza Vaccine Revenue by Country (2018-2034)
6.4.3 North America Pandemic Influenza Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pandemic Influenza Vaccine Sales by Company
7.1.1 Europe Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024)
7.1.2 Europe Pandemic Influenza Vaccine Revenue by Company (2018-2024)
7.2 Europe Pandemic Influenza Vaccine Market Size by Type
7.2.1 Europe Pandemic Influenza Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Pandemic Influenza Vaccine Revenue by Type (2018-2034)
7.3 Europe Pandemic Influenza Vaccine Market Size by Application
7.3.1 Europe Pandemic Influenza Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Pandemic Influenza Vaccine Revenue by Application (2018-2034)
7.4 Europe Pandemic Influenza Vaccine Market Size by Country
7.4.1 Europe Pandemic Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Pandemic Influenza Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Pandemic Influenza Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pandemic Influenza Vaccine Sales by Company
8.1.1 China Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024)
8.1.2 China Pandemic Influenza Vaccine Revenue by Company (2018-2024)
8.2 China Pandemic Influenza Vaccine Market Size by Type
8.2.1 China Pandemic Influenza Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Pandemic Influenza Vaccine Revenue by Type (2018-2034)
8.3 China Pandemic Influenza Vaccine Market Size by Application
8.3.1 China Pandemic Influenza Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Pandemic Influenza Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pandemic Influenza Vaccine Sales by Company
9.1.1 APAC Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024)
9.1.2 APAC Pandemic Influenza Vaccine Revenue by Company (2018-2024)
9.2 APAC Pandemic Influenza Vaccine Market Size by Type
9.2.1 APAC Pandemic Influenza Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Pandemic Influenza Vaccine Revenue by Type (2018-2034)
9.3 APAC Pandemic Influenza Vaccine Market Size by Application
9.3.1 APAC Pandemic Influenza Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Pandemic Influenza Vaccine Revenue by Application (2018-2034)
9.4 APAC Pandemic Influenza Vaccine Market Size by Region
9.4.1 APAC Pandemic Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Pandemic Influenza Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Pandemic Influenza Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Pandemic Influenza Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pandemic Influenza Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pandemic Influenza Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 CSL
11.1.1 CSL Company Information
11.1.2 CSL Overview
11.1.3 CSL Pandemic Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 CSL Pandemic Influenza Vaccine Products and Services
11.1.5 CSL Pandemic Influenza Vaccine SWOT Analysis
11.1.6 CSL Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Pandemic Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 GSK Pandemic Influenza Vaccine Products and Services
11.2.5 GSK Pandemic Influenza Vaccine SWOT Analysis
11.2.6 GSK Recent Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Company Information
11.3.2 Sanofi Pasteur Overview
11.3.3 Sanofi Pasteur Pandemic Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Sanofi Pasteur Pandemic Influenza Vaccine Products and Services
11.3.5 Sanofi Pasteur Pandemic Influenza Vaccine SWOT Analysis
11.3.6 Sanofi Pasteur Recent Developments
11.4 Mylan
11.4.1 Mylan Company Information
11.4.2 Mylan Overview
11.4.3 Mylan Pandemic Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Mylan Pandemic Influenza Vaccine Products and Services
11.4.5 Mylan Pandemic Influenza Vaccine SWOT Analysis
11.4.6 Mylan Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Overview
11.5.3 AstraZeneca Pandemic Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 AstraZeneca Pandemic Influenza Vaccine Products and Services
11.5.5 AstraZeneca Pandemic Influenza Vaccine SWOT Analysis
11.5.6 AstraZeneca Recent Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Pandemic Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Pfizer Pandemic Influenza Vaccine Products and Services
11.6.5 Pfizer Pandemic Influenza Vaccine SWOT Analysis
11.6.6 Pfizer Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Overview
11.7.3 Johnson & Johnson Pandemic Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Johnson & Johnson Pandemic Influenza Vaccine Products and Services
11.7.5 Johnson & Johnson Pandemic Influenza Vaccine SWOT Analysis
11.7.6 Johnson & Johnson Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pandemic Influenza Vaccine Value Chain Analysis
12.2 Pandemic Influenza Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pandemic Influenza Vaccine Production Mode & Process
12.4 Pandemic Influenza Vaccine Sales and Marketing
12.4.1 Pandemic Influenza Vaccine Sales Channels
12.4.2 Pandemic Influenza Vaccine Distributors
12.5 Pandemic Influenza Vaccine Customers
13 Market Dynamics
13.1 Pandemic Influenza Vaccine Industry Trends
13.2 Pandemic Influenza Vaccine Market Drivers
13.3 Pandemic Influenza Vaccine Market Challenges
13.4 Pandemic Influenza Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pandemic Influenza Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Whole Virus Vaccines
Table 3. Major Manufacturers of Split Virus Vaccines
Table 4. Major Manufacturers of Subunit Vaccines
Table 5. Global Pandemic Influenza Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Pandemic Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Pandemic Influenza Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Pandemic Influenza Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Pandemic Influenza Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Pandemic Influenza Vaccine Revenue Market Share by Region (2024-2034)
Table 11. Global Pandemic Influenza Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Doses)
Table 12. Global Pandemic Influenza Vaccine Sales by Region (2018-2024) & (K Doses)
Table 13. Global Pandemic Influenza Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Pandemic Influenza Vaccine Sales by Region (2024-2034) & (K Doses)
Table 15. Global Pandemic Influenza Vaccine Sales Market Share by Region (2024-2034)
Table 16. Global Pandemic Influenza Vaccine Sales Quantity by Manufacturers (2018-2024) & (K Doses)
Table 17. Global Pandemic Influenza Vaccine Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Pandemic Influenza Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Pandemic Influenza Vaccine Revenue Share by Manufacturers (2018-2024)
Table 20. Global Pandemic Influenza Vaccine Price by Manufacturers 2018-2024 (USD/Dose)
Table 21. Global Key Players of Pandemic Influenza Vaccine, Industry Ranking, 2021 VS 2022
Table 22. Global Pandemic Influenza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Pandemic Influenza Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pandemic Influenza Vaccine as of 2022)
Table 24. Global Key Manufacturers of Pandemic Influenza Vaccine, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Pandemic Influenza Vaccine, Product Offered and Application
Table 26. Global Key Manufacturers of Pandemic Influenza Vaccine, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Pandemic Influenza Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 29. Global Pandemic Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 30. Global Pandemic Influenza Vaccine Sales Quantity Share by Type (2018-2024)
Table 31. Global Pandemic Influenza Vaccine Sales Quantity Share by Type (2024-2034)
Table 32. Global Pandemic Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Pandemic Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Pandemic Influenza Vaccine Revenue Share by Type (2018-2024)
Table 35. Global Pandemic Influenza Vaccine Revenue Share by Type (2024-2034)
Table 36. Pandemic Influenza Vaccine Price by Type (2018-2024) & (USD/Dose)
Table 37. Global Pandemic Influenza Vaccine Price Forecast by Type (2024-2034) & (USD/Dose)
Table 38. Global Pandemic Influenza Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 39. Global Pandemic Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 40. Global Pandemic Influenza Vaccine Sales Quantity Share by Application (2018-2024)
Table 41. Global Pandemic Influenza Vaccine Sales Quantity Share by Application (2024-2034)
Table 42. Global Pandemic Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Pandemic Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Pandemic Influenza Vaccine Revenue Share by Application (2018-2024)
Table 45. Global Pandemic Influenza Vaccine Revenue Share by Application (2024-2034)
Table 46. Pandemic Influenza Vaccine Price by Application (2018-2024) & (USD/Dose)
Table 47. Global Pandemic Influenza Vaccine Price Forecast by Application (2024-2034) & (USD/Dose)
Table 48. North America Pandemic Influenza Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 50. North America Pandemic Influenza Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 51. North America Pandemic Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 52. North America Pandemic Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Pandemic Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Pandemic Influenza Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 55. North America Pandemic Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 56. North America Pandemic Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Pandemic Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Pandemic Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Pandemic Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Pandemic Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Pandemic Influenza Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 62. North America Pandemic Influenza Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 63. Europe Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 64. Europe Pandemic Influenza Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Pandemic Influenza Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 66. Europe Pandemic Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 67. Europe Pandemic Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Pandemic Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Pandemic Influenza Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 70. Europe Pandemic Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 71. Europe Pandemic Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Pandemic Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Pandemic Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Pandemic Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Pandemic Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Pandemic Influenza Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 77. Europe Pandemic Influenza Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 78. China Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 79. China Pandemic Influenza Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Pandemic Influenza Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 81. China Pandemic Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 82. China Pandemic Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Pandemic Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Pandemic Influenza Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 85. China Pandemic Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 86. China Pandemic Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Pandemic Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 89. APAC Pandemic Influenza Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Pandemic Influenza Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 91. APAC Pandemic Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 92. APAC Pandemic Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Pandemic Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Pandemic Influenza Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 95. APAC Pandemic Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 96. APAC Pandemic Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Pandemic Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Pandemic Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Pandemic Influenza Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Pandemic Influenza Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Pandemic Influenza Vaccine Sales Quantity by Region (2018-2024) & (K Doses)
Table 102. APAC Pandemic Influenza Vaccine Sales Quantity by Region (2024-2034) & (K Doses)
Table 103. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Company (2018-2024) & (K Doses)
Table 104. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Type (2018-2024) & (K Doses)
Table 106. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 107. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Application (2018-2024) & (K Doses)
Table 110. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 111. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Country (2018-2024) & (K Doses)
Table 117. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 118. CSL Company Information
Table 119. CSL Description and Overview
Table 120. CSL Pandemic Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 121. CSL Pandemic Influenza Vaccine Product and Services
Table 122. CSL Pandemic Influenza Vaccine SWOT Analysis
Table 123. CSL Recent Developments
Table 124. GSK Company Information
Table 125. GSK Description and Overview
Table 126. GSK Pandemic Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 127. GSK Pandemic Influenza Vaccine Product and Services
Table 128. GSK Pandemic Influenza Vaccine SWOT Analysis
Table 129. GSK Recent Developments
Table 130. Sanofi Pasteur Company Information
Table 131. Sanofi Pasteur Description and Overview
Table 132. Sanofi Pasteur Pandemic Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 133. Sanofi Pasteur Pandemic Influenza Vaccine Product and Services
Table 134. Sanofi Pasteur Pandemic Influenza Vaccine SWOT Analysis
Table 135. Sanofi Pasteur Recent Developments
Table 136. Mylan Company Information
Table 137. Mylan Description and Overview
Table 138. Mylan Pandemic Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 139. Mylan Pandemic Influenza Vaccine Product and Services
Table 140. Mylan Pandemic Influenza Vaccine SWOT Analysis
Table 141. Mylan Recent Developments
Table 142. AstraZeneca Company Information
Table 143. AstraZeneca Description and Overview
Table 144. AstraZeneca Pandemic Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 145. AstraZeneca Pandemic Influenza Vaccine Product and Services
Table 146. AstraZeneca Pandemic Influenza Vaccine SWOT Analysis
Table 147. AstraZeneca Recent Developments
Table 148. Pfizer Company Information
Table 149. Pfizer Description and Overview
Table 150. Pfizer Pandemic Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 151. Pfizer Pandemic Influenza Vaccine Product and Services
Table 152. Pfizer Pandemic Influenza Vaccine SWOT Analysis
Table 153. Pfizer Recent Developments
Table 154. Johnson & Johnson Company Information
Table 155. Johnson & Johnson Description and Overview
Table 156. Johnson & Johnson Pandemic Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2024)
Table 157. Johnson & Johnson Pandemic Influenza Vaccine Product and Services
Table 158. Johnson & Johnson Pandemic Influenza Vaccine SWOT Analysis
Table 159. Johnson & Johnson Recent Developments
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Pandemic Influenza Vaccine Distributors List
Table 163. Pandemic Influenza Vaccine Customers List
Table 164. Pandemic Influenza Vaccine Market Trends
Table 165. Pandemic Influenza Vaccine Market Drivers
Table 166. Pandemic Influenza Vaccine Market Challenges
Table 167. Pandemic Influenza Vaccine Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Pandemic Influenza Vaccine Product Picture
Figure 2. Global Pandemic Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pandemic Influenza Vaccine Market Share by Type in 2022 & 2034
Figure 4. Whole Virus Vaccines Product Picture
Figure 5. Split Virus Vaccines Product Picture
Figure 6. Subunit Vaccines Product Picture
Figure 7. Global Pandemic Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Pandemic Influenza Vaccine Market Share by Application in 2022 & 2034
Figure 9. For Children (6 months to 3 years)
Figure 10. For Adults and Children over 3 years
Figure 11. Pandemic Influenza Vaccine Report Years Considered
Figure 12. Global Pandemic Influenza Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Pandemic Influenza Vaccine Revenue 2018-2034 (US$ Million)
Figure 14. Global Pandemic Influenza Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Pandemic Influenza Vaccine Sales Quantity 2018-2034 (K Doses)
Figure 16. Global Pandemic Influenza Vaccine Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Pandemic Influenza Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Pandemic Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 19. North America Pandemic Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Pandemic Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 21. Europe Pandemic Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Pandemic Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 23. China Pandemic Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Pandemic Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 25. APAC Pandemic Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 27. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Pandemic Influenza Vaccine Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Pandemic Influenza Vaccine Revenue in 2022
Figure 30. Pandemic Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Pandemic Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 33. Global Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Pandemic Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 35. North America Pandemic Influenza Vaccine Revenue Market Share by Company in 2022
Figure 36. North America Pandemic Influenza Vaccine Sales Quantity Market Share by Company in 2022
Figure 37. North America Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Pandemic Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 39. North America Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Pandemic Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 41. North America Pandemic Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 42. North America Pandemic Influenza Vaccine Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Pandemic Influenza Vaccine Sales Quantity Market Share by Company in 2022
Figure 46. Europe Pandemic Influenza Vaccine Revenue Market Share by Company in 2022
Figure 47. Europe Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Pandemic Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 49. Europe Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Pandemic Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 51. Europe Pandemic Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 52. Europe Pandemic Influenza Vaccine Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 54. France Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 58. China Pandemic Influenza Vaccine Sales Quantity Market Share by Company in 2022
Figure 59. China Pandemic Influenza Vaccine Revenue Market Share by Company in 2022
Figure 60. China Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Pandemic Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 62. China Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Pandemic Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 64. APAC Pandemic Influenza Vaccine Sales Quantity Market Share by Company in 2022
Figure 65. APAC Pandemic Influenza Vaccine Revenue Market Share by Company in 2022
Figure 66. APAC Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Pandemic Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 68. APAC Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Pandemic Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 70. APAC Pandemic Influenza Vaccine Revenue Share by Region (2018-2034)
Figure 71. APAC Pandemic Influenza Vaccine Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. India Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Pandemic Influenza Vaccine Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Pandemic Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 85. Brazil Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Pandemic Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 90. Pandemic Influenza Vaccine Value Chain
Figure 91. Pandemic Influenza Vaccine Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries